To begin to assess the involvement of RelB in breast cancer, the ZR-75, MCF-7 and T47D ERα-positive, and Hs578T and MDA-MB-231 ERα-negative human breast cancer cells, and the low expresser NF639 mouse mammary tumour line were selected. Immunoblot analysis of whole cell protein extracts (WCEs) confirmed the expected profile of ERα (Fig. 1a) . Abundant levels of RelB protein were observed in Hs578T and MDA-MB-231 cells, whereas RelB levels were extremely low in ZR-75, MCF-7 and T47D cells; NF639 cells had an intermediate level (Fig. 1a) . Total levels of RelB and ERα proteins displayed an inverse relationship (Fig. 1b) . The difference in RelB expression in the cell lines was even more striking when the nuclear compartment was examined (Fig. 1a, b) . Levels of RELB mRNA were also much higher in ERα-negative versus ERα-positive breast cancer cells (Fig. 1c) . To determine whether an inverse correlation similarly exists in primary human breast cancers, a microarray gene expression dataset obtained from 295 patients and publicly available at Oncomine.org was analysed 6 . The levels of RELB mRNA were significantly higher in ERα-negative versus ERα-positive breast cancers ( Fig. 1d ; P = 3.9 e -11 , Student's t-test), consistent with the cell-line data. Analysis of microarray datasets from three other studies confirmed this inverse correlation, including one with similar numbers of patient samples 7 (P = 2.7 e -7
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Levels of RELB mRNA were also much higher in ERα-negative versus ERα-positive breast cancer cells (Fig. 1c) . To determine whether an inverse correlation similarly exists in primary human breast cancers, a microarray gene expression dataset obtained from 295 patients and publicly available at Oncomine.org was analysed 6 . The levels of RELB mRNA were significantly higher in ERα-negative versus ERα-positive breast cancers ( Fig. 1d ; P = 3.9 e -11 , Student's t-test), consistent with the cell-line data. Analysis of microarray datasets from three other studies confirmed this inverse correlation, including one with similar numbers of patient samples 7 (P = 2.7 e -7
). Thus, RELB mRNA levels correlate inversely with ERα status in primary human breast cancers.
In de novo RelB synthesis mediated by the CMV IE1 protein, induction of binding of active c-Jun-Fra-2 AP-1 and p50-p65 NF-κB complexes to one distal AP-1 and two proximal κB elements, respectively, was shown to synergistically activate the RELB promoter in NIH3T3 and smooth muscle cells 3 , whereas c-Jun-c-Fos AP-1 was inactive. Electrophoretic mobility shift assays (EMSAs) showed that ERα-negative or ERα-low cells displayed much higher basal levels of AP-1 and NF-κB binding compared with the ERα-positive lines, as previously reported 1, 8 (Fig. 1e ). Immunoblot analysis detected higher nuclear levels of Fra-2, c-Jun, and Fra-1 in ERα-negative or low versus ERα-positive cells, whereas JunB, and to a lesser extent JunD and c-Fos, were elevated in ERα-positive cells (Fig. 1f) .
To examine de novo RelB synthesis, transfection analysis was performed with the RELB promoter and vectors expressing various AP-1 subunits in Hs578T cells, which display constitutive p50-p65 NF-κB activity 9 . Ectopic expression of c-Jun or Fra-2 alone led to an approximate six or threefold activation of RELB promoter, respectively (Fig. 2a) , whereas coexpression induced RELB promoter activity by ~26-fold (Fig. 2a) . Similar synergy was observed in MDA-MB-231 and NF639 cells, whereas only an additive effect on RELB promoter activity was observed in the three ERα-positive cell lines (Fig. 2b) . Expression of c-Fos alone or in combination with c-Jun was unable to substantially induce RELB promoter activity. Somewhat surprisingly, Fra-1, which was moderately active in NIH3T3 cells
To examine whether the synergy observed was due to the high endogenous NF-κB activity in ERα-negative cells, the NF-κB inhibitory protein IκB-α was coexpressed in Hs578T and MCF-7 cells. IκB-α expression strongly blocked the synergy between c-Jun and Fra-2 in Hs578T cells, although it had little effect in MCF-7 cells or on c-Jun and Fra-2 alone (Fig. 2c) . When a RELB promoter construct with mutated κB elements was analysed, the coexpression of c-Jun and Fra-2 led to activation that was only additive in ERα-negative cells (Fig. 2d) , confirming the role of NF-κB in the observed synergy.
To directly examine the roles of c-Jun and Fra-2 in MDA-MB-231 and Hs578T cells, JUN short interfering RNA (siRNA) or FRA2 siRNA was used, which successfully reduced endogenous c-Jun and Fra-2 levels when added alone or in combination (Fig. 2e) . Knockdown of c-Jun alone had little effect on RelB expression in MDA-MB-231, but substantially decreased RelB levels in Hs578T cells. An ~30-40% reduction in RelB levels was observed in both lines on knockdown of Fra-2 alone. When both AP-1 subunits were reduced, an ~50-90% decrease in RelB levels occurred (Fig. 2e) , confirming the role of c-Jun-Fra-2 heterodimers in activation of endogenous RelB. In addition, the ability of c-Jun-Fra-2 and p50-p65 to act in synergy was directly examined using reduced suboptimal doses of each expression vector. A potent induction of RELB promoter activity was observed in both ERα-negative and -positive cells (Fig. 2f) . In contrast, Fra-2 and JunB, which are highly expressed in ERα-positive cells, were unable to induce RELB promoter activity (data 6 was accessed using the ONCOMINE Cancer Profiling Database and is plotted on a log scale. The dataset included n = 69 ERα-negative and n = 226 ERα-positive human primary breast carcinoma samples. A Student's t-test, performed directly through the Oncomine 3.0 software, showed the difference in RELB expression between the two groups was significant (P = 3.9 e -11 ). The lines (whiskers) emerging from each box extend to the smallest and largest observations. (e) Nuclear extracts (5 μg) were subjected to EMSA binding of AP-1, NF-κB or Oct-1, which confirmed equal loading. The positions of the previously identified p50-p50 and p50-p65 NF-κB complexes in Hs578T cells 9 are as indicated. (f) Nuclear extracts (25 μg) were analysed for Fra-2, c-Jun, Fra-1, c-Fos, JunB, JunD or β-actin. Uncropped images of the scans of the top two panels in a and e are shown in the Supplementary Information, Fig. S5a and S5b, respectively. not shown). Thus, c-Jun-Fra-2 AP-1 and p50-p65 NF-κB complexes, which are highly expressed in ERα-negative or ERα-low breast cancer cells, work in synergy to induce de novo RelB synthesis.
To assess the role of ERα in de novo RelB synthesis, MCF-7 and T47D cells were treated with the anti-estrogen ICI 182,780, which inhibits oestrogen-dependent ERα function 10 and decreases ERα protein levels ( Fig. 3a) . ICI 182,780 treatment increased RelB protein and RNA levels ( Fig. 3a) , and induced both NF-κB and AP-1 DNA binding and activity (Fig. 3b , c and see Supplementary Information, Fig. S1a ). Similarly, siRNA-induced knockdown of ERα substantially increased RelB levels in MCF-7 cells (Fig. 3d) . The effects of ectopic ERα expression were assessed in MDA-MB-231 and Hs578T cells in the presence of 17β-oestradiol (E2). Activation of ERα signalling substantially decreased RelB protein levels in MDA-MB-231 (61.8%) and Hs578T (47.4%) cells (Fig. 3e) . To examine the effects of active ERα on de novo RelB synthesis, RELB promoter constructs were used in MDA-MB-231 cells. Mutation of either the κB or AP-1 site partially reduced basal promoter activity, and the double mutation resulted in an ~90% reduction, confirming the roles of the two factors in control of RELB promoter transcription. Ectopic ERα signalling resulted in strong repression of the wild-type RELB promoter, but only partial or no inhibition of the promoters with mutations in either the κB or AP-1 site or with a double mutation, respectively, was observed (Fig. 3f) . Thus, ERα signalling effectively represses RELB promoter activity driven by NF-κB and AP-1.
Although the mechanisms mediating repression of NF-κB by ERα have been extensively studied 12 , little is known about how ERα represses AP-1. We noted that ERα-negative cells have higher levels of Fra-2 compared with ERα-positive cells, which led us to hypothesize that ERα signalling represses Fra-2 expression, and thereby AP-1 activity. Consistent with this hypothesis, inhibition of ERα in MCF-7 cells led to an increase in Fra-2 levels, whereas c-Jun was unaffected (Fig. 3g) . Conversely, ectopic ERα signalling in MDA-MB-231 or Hs578T cells decreased Fra-2 expression (Fig. 3h) . Knockdown of ERα in MCF-7 cells led to an increase in Fra-2 at day 1, which preceded the increase in RelB levels that were noted after 2 days (Fig. 3i) . Similarly, induction of ERα signalling in MDA-MB-231 decreased Fra-2 levels after one day, preceding the decrease in RelB levels detectable after day 2 (Fig. 3j) . Thus, repression of Fra-2 by ERα has a significant role in inhibition of de novo RelB synthesis.
Highly invasive and metastatic breast cancers are frequently ERα-negative [13] [14] [15] . To examine the role of RelB in invasive phenotype, Hs578T cells with knockdown of RelB (RELB siRNA) or control sense RelB cells (control siRNA) were prepared (Fig. 4) . Expression of Snail, the repressor of E-cadherin gene (CDH1) transcription, was decreased in RELB siRNA cells at both the mRNA and protein level (Figs. 4a, b) . Furthermore, levels of the epithelial markers E-cadherin and γ-catenin were increased in RELB siRNA cells (Fig. 4b) . A substantial decrease in fibronectin protein expression, a mesenchymal marker, was also observed. Importantly, RELB siRNA cells displayed decreased motility (Fig. 4c ) and ability to form invasive colonies in Matrigel (Fig. 4d) . Thus, RelB expression is required for maintenance of mesenchymal phenotype of ERα-negative Hs578T breast cancer cells.
To determine whether ectopic expression of RelB can promote a more mesenchymal phenotype in ERα-positive breast cancer cells, MCF-7 cells were transfected with pcDNA3-RELB expression vector or parental pcDNA3 EV DNA (MCF-7-RELB and MCF-7-EV, respectively), and several independent stable clones (MCF-7-RELB) expressing elevated RelB levels were isolated (Fig. 4e-h ). RelB overexpression was sufficient to lead to a marked decrease in E-cadherin levels ( Fig. 4e and see Supplementary Information, Fig. S2 ). RelB also increased levels of fibronectin, and vimentin, another mesenchymal marker (Fig. 4e) .
Stable RelB overexpression resulted in a more than fivefold increase in migration of MCF-7 cells (Fig. 4f) , enhanced cell scattering (Fig. 4g ) and increased invasion through Matrigel (1.7-fold; 0.43 ± 0.08 versus 0.25 ± 0.06). RelB overexpression also led to increased colony size in Matrigel (Fig. 4h) , although it was insufficient to allow for branching colony formation. Furthermore, induction of RelB led to a more invasive gene profile within 48 h (Fig. 4i) , and to a 4.7-fold increase in migration (data not shown). Thus, RelB expression in ERα-positive breast cancer cells decreases epithelial and increases mesenchymal characteristics.
To further monitor the oncogenic effects of RelB expression, cells were irradiated and RelB was found to greatly promote resistance to killing (X.W., K.B., H. Ying, Z.X. Xiao & G.E.S., unpublished observations). This led us to examine the effects of RelB on expression of the pro-survival Bcl-2 protein, product of an NF-κB p50-RelA target gene 16 . Inhibition of RelB led to a decrease in Bcl-2 protein levels in Hs578T cells, whereas ectopic RelB induced its expression in MCF-7 cells (Fig. 5a) . Consistently, endogenous Bcl-2 levels were higher in the ERα-negative Hs578T and MDA-MB-231 lines compared with ERα-positive ZR-75 and MCF-7 cells (Fig. 5b) . To begin to test for transcriptional activation of the BCL2 gene by RelB, we first confirmed that RelB levels controlled BCL2 mRNA expression (Fig. 5a ). The BCL2 gene has a TATA-less major P1 promoter, responsible for 95% of BCL2 gene transcription, and a minor P2 promoter 20 . In Hs578T cells, cotransfection of the wild-type BCL2 P1 reporter construct with the RELB siRNA vector, led to an approximately fivefold decrease in its activity compared with the sense control siRNA (Fig. 5c) . Furthermore, the activity of the wild-type BCL2 P1 promoter was potently induced on cotransfection of vectors expressing RelB and p52 in either Hs578T cells (Fig 5d) or ZR-75 cells (see Supplementary Information, Fig. S3c) . Induction of P1 promoter activity by NF-κB in B cells has been shown to be mediated indirectly via protein-protein interaction with CREB, which is bound to a cyclic AMP response element (CRE) at base pairs -1535 to -1552 (ref. 17) . When the CRE mutant and wild-type constructs were compared, the activity of the mutant BCL2 construct in Hs578T cells expressing the control siRNA vector was significantly lower (Fig. 5c) , and was unable to be substantially activated on ectopic expression of RelB-p52 in either Hs578T cells (Fig 5d) or ZR-75 cells (see Supplementary Information, Fig. S3c ). Thus, RelB regulates BCL2 promoter activity in breast cancer cells.
Recent evidence has correlated enhanced Bcl-2 levels with progression to a metastatic phenotype in prostate cancer 18 , leading us to hypothesize Bcl-2 mediates the effects of RelB. Ectopic Bcl-2 expression in MCF-7 and ZR-75 cells substantially decreased expression of E-cadherin and γ-catenin, whereas levels of the upstream regulator RelB were unaffected; migration of MCF-7 cells was enhanced (Fig. 5e, f) . Ectopic Bcl-2 expression also resulted in a substantial decrease in E-cadherin staining in MCF-7 cells (see Supplementary Information, Fig. S4 ). We examined the ability of ectopic Bcl-2 to reverse the effects of inhibition of RelB in Hs578T cells. Ectopic Bcl-2 decreased expression of E-cadherin and γ-catenin, and essentially restored the ability of RELB siRNA-treated Hs578T cells to migrate and to form colonies with invasive phenotype in Matrigel (Fig. 5g-i) . Finally, knockdown of Bcl-2 decreased the ability of the Hs578T cells to form invasive colonies and to migrate (Fig. 5j-k) , in association with increased E-cadherin and γ-catenin (Fig. 5l) . Taken together, the data argue that Bcl-2 is a critical mediator of invasive properties induced by RelB. 
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RELB ( Hs578T transfectants expressing either RELB siRNA or sense RELB (control siRNA) were prepared. Expression of RELB siRNA decreased levels of RELB mRNA and RelB protein in the nucleus, but had no effect on levels of the p65 NF-κB subunit (see Supplementary  Information, Figs . S1b1 and S1b2), consistent with previous observations 33 .
(a) RNA was analysed by RT-PCR for levels of SNAI1 and GAPDH RNA, as a control for equal loading. (b) WCEs (50 μg) were analysed by immunoblotting for E-cadherin, γ-catenin, Snail, fibronectin (FN) and β-actin. The effects of RELB siRNA on MDA-MB-231 cells were tested and similar data were obtained (see Supplementary Information, Fig. S1c ). (c) Cells were subjected, in triplicate, to a migration assay for 4 h. Cells that migrated to the lower side of the filter quantified by spectrometric determination at A 410 . Average migration from three independent experiments is presented relative to control siRNA (set at 100%). Data presented are from one representative of three experiments. (d) Cells were subjected to Matrigel outgrowth analysis. After 5 days, the colonies were photographed (50× magnification). (e-h) Stable MCF-7 clones expressing either RELB or EV DNA were isolated: RELB(1), RELB(2), EV(1) and EV (2) . Ectopic RelB expression increased NF-κB reporter activity, and levels of cyclin D1, but failed to alter the levels of p65 (see Supplementary Information, Figs. S3a  and 3b) . (e) WCEs were subjected to immunoblot analysis for E-cadherin (E-cad), fibronectin (FN), vimentin (Viment) and β-actin. Although all of the clones showed an increase in fibronectin, the extent of the increase varied. (f) Clones were subjected to a migration assay, as in c (from three separate experiments). (g) MCF-7 stable clones (1 × 10 4 cells ml -1
) were plated and after 2 days photographed (50× magnification). (h) Clones were subjected to Matrigel outgrowth analysis. After 15 days of growth, the colonies were photographed (50× magnification). (i) Stable MCF-7 cells with an inducible RelB expression vector were treated with 1 µg ml -1 doxycyline. After 48 h, WCEs were subjected to immunoblot analysis for RelB, E-cadherin (E-cad), vimentin and β-actin, as above. The scale bars represent 100 μm in d, g and h. An uncropped image of the scan of the E-cadherin panel in i is shown in the Supplementary Information, Fig. S5c .
Here, we show the ability of ERα to reduce AP-1 and NF-κB binding and activity, and thereby to suppress de novo RelB synthesis, which represents a new mechanism whereby receptor signalling maintains a more epithelial phenotype. The effects on AP-1 were mediated, in large measure, by inhibition of Fra-2. Thus, transcriptional regulatory mechanisms control RelB NF-κB activation and function. Although were prepared from MCF-7 and ZR-75 cells, ectopically expressing EV or full-length Bcl-2, and analysed for EMT gene expression, Bcl-2 and RelB, as above. (f) Stable mixed populations of MCF-7 cells expressing Bcl-2 or EV DNA were subjected to a migration assay for 24 h, as in Fig. 4c (two independent experiments). (g) WCEs (50 µg) were prepared from RELB siRNA cells, ectopically expressing full-length Bcl-2, and analysed, as above.
(h-i) RELB siRNA Hs578T cells were transiently infected with pBABE-Bcl-2 or EV pBABE DNA. After 24 h, cells were subjected to a migration assay for 4 h (two independent experiments; h), or Matrigel colony formation assay for 12 days (i). (j-l) Hs578T cells were infected with pSM2c-BCL2 shRNA or scrambled control (Control). Cells were subjected to Matrigel assay in the presence of 2 µg ml -1 puromycin (j). Stable mixed populations, isolated using puromycin selection, were subjected to a migration assay for 4 h (three independent experiments; k). (l) WCEs (25 µg) were assessed by immunoblotting. The scale bars represent 100 µm in i and j.
early reports of RelB function implicated this subunit in mediating signals in the adaptive immune response 19 , recent studies have provided evidence for a role of RelB in cancer. We noted that several mammary tumours in MMTV-c-Rel transgenic mice expressed elevated nuclear levels of RelB 4 , and p52-RelB complexes were induced in mouse mammary tumours following carcinogen treatment 5 . p50-RelB was observed in mucosa-associated lymphoid tissue lymphomas, and these complexes inhibited apoptosis induced on DNA damage 20 . RelB was the most frequently detected NF-κB subunit in the nuclei of prostate cancer tissue, correlated directly with Gleason score 21 and had a radioprotective role in aggressive prostate cancer cells 22 . Here, higher levels of RelB observed in ERα-negative breast cancer cell lines and human breast cancers suggest an important role for RelB in advanced breast carcinomas. Consistent with our observations, RelB was recently implicated in inflammatory breast disease 23 . It was also reported that NF-κB activity was essential for the induction and maintenance of EMT and metastasis of Ras-transformed epithelial breast cells by TGF-β1 (ref. 24) . We demonstrated that elevated NF-κB activity is critical for maintenance of EMT in a c-Rel-driven mammary tumour cell line following carcinogen treatment 25 . For the first time, we elucidate a critical role for RelB in EMT in breast cancer cells, and identify Bcl-2 as an important downstream mediator. RelB-p52 complexes were shown to induce BCL2 P1 promoter activity. Protection from apoptosis by such genes as BCL2 has recently been proposed to have an important role in promoting metastasis 18 : for example, ectopic expression of Bcl-2 in lymphomas increased their ability to metastasize to the lung 26 . Our data indicate a role for Bcl-2 in negative regulation of epithelial markers. Interestingly, Bcl-2 has recently been shown to promote the degradation of IκB-α and thereby induce NF-κB activity in cardiac myocytes 27 . This suggests a feed-forward mechanism, that is, induction of Bcl-2 further enhances NF-κB activity, which promotes a mesenchymal phenotype. Experiments are in progress to test this model in breast cancer cells. ERα was previously shown to inhibit EMT through its control of MTA3 levels and repression of SNAI1 gene transcription 28 . Our findings indicate inhibition of de novo RelB synthesis represents an additional mechanism by which ERα can control EMT, which provides a unifying model for the observed involvement of NF-κB and AP-1 activities in EMT. Future studies exploring the role of RelB as a biomarker or in therapeutic approaches for treatment of metastatic breast disease are warranted.
METHODS
Cell culture and treatment conditions. The NF639 cell line was derived from a mammary gland tumour in a mammary tumour virus (MMTV)-ERBB2 transgenic mouse and cultured as previously described 29 . ERα-positive MCF-7, T47D and ZR-75 cells, and ERα-negative Hs578T and MDA-MB-231 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA) and maintained in standard culturing medium as recommended by ATCC. Cultures were stripped of endogenous steroids by successive passages in phenol red-free medium containing 10% dextran-coated charcoal-stripped fetal bovine serum (DCC-FBS; 2 days), and then 3% DCC-FBS (3 days) 30 . MCF-7 cell lines containing pcDNA3 or pcDNA3-RELB and Hs578T cell lines containing human pRELB siRNA or control pRELB sense (control siRNA) were established as previously described 5 and grown in the presence of 400 μg ml -1 G418 (Sigma, St Louis, MO) or 1 μg ml -1 puromycin (Sigma), respectively. MCF-7 and RELB siRNA Hs578T cell lines containing pBABE and pBABE-Bcl-2 were established by retroviral infection, as previously described 31 , and used 24 h post infection. Hs578T cells carrying pSM2c-BCL2 short hairpin RNA (shRNA; V2HS_ 111806, Open Biosystems, Huntsville, AL) or scrambled control were established by retroviral infection, as above. MCF-7 cells containing inducible C4 bsr R(TO) or C4 bsr R(TO-RelB) were established as previously described 32 . Expression of RelB was induced by treatment with 1 μg ml -1 doxycycline for 48 h and analysed as described. Where indicated, cells were treated with 1 μM ICI 182,780 or equivalent volume of vehicle ethanol (Tocris Cookson, Ellisville, MO). E2 was purchased from Sigma.
Plasmids and transfection analysis. The human 1.7 kB RELB promoter driving a luciferase reporter in pGL3 basic vector (p1.7 RELB promoter-Luc) and the pcDNA3-RELB construct containing human RELB cDNA sequence in the pcDNA3 expression vector were as described previously 3 . The pC4 bsr R(TO-RelB) construct was generated by subcloning the Relb cDNA into the EcoRI restriction site of the doxycycline inducible pC4 bsr R(TO) retroviral vector. The p1.7 RELB promoter-Luc vectors containing either wild-type or mutant NF-κB (κB Mut ), or AP-1 (AP1 Mut ) elements alone or with the double mutation were as prepared previously 3 . The thymidine kinase promoter-driven luciferase reporter plasmid controlled by six reiterated κB sites, was kindly provided by G. Rawadi (HoechstMarion-Roussel, Romainville, France). The thymidine kinase promoter-driven chloramphenicol acetyl transferase (CAT) plasmid controlled by five copies of the TPA responsive elements (TRE), was as described previously 3 . The NF-κB p50 or p65 constructs in pMT2T expression vector were as reported 3 . The IκBα construct containing IκBα SS32/36AA mutant in pRC-β-actin expression vector, was as previously reported 5 . The c-Jun, c-Fos, Fra-1 and Fra-2 AP-1 family member constructs in the pCI expression vector were as previously reported 3 . pRELB sense and pRELB siRNA-containing control or RELB siRNA oligonucleotides in pSIREN-RetroQ vector, were described previously 33 . The human full-length BCL2 constructs in pcDNA3 or pBabe were as previously reported 34 . The SV40 β-galactosidase (β-gal) reporter vector was as reported 3 . For transfection into six-well and P100 plates, 3 or 10 μg total DNA was transfected, respectively. For transient transfection, cultures were incubated for 48 h in the presence of DNA and Fugene6 (Roche Diagnostics Co., Indianapolis, IN) or Geneporter2 (Gene Therapy System Inc., San Diego, CA) transfection reagent. All transient transfections were performed a minimum of three times, in triplicate. For stable transfection, cells were incubated for 48 h with DNA and GenePorter2 before adding 10 μg ml -1 blasticidin, 400 μg ml -1 G418 or 1 μg ml -1 puromycin, as appropriate, for stable selection. CAT and luciferase assays were performed as previously described 2, 4 . Cotransfection of the SV40-β-gal expression vector was used to normalize for transfection efficiency, as previously described 4 . Sequences of FRA2, JUN and GFP siRNA duplexes have been previously described 35 . For the RelB repression studies, the ERα siRNA duplex (Dharmacon, Chicago, IL) targeted the following sequence: AAGATCCTGAAACAGAGCATG (sense strand). Transfections (100 nM final) were carried out using Oligofectamine (Invitrogen, Carlsbad, CA), in Optimem serum-free medium, 24 h after plating. When multiple transfections were performed, cells were replated 48 h after transfection (dilution 1:2). For kinetics studies, cell extracts were processed for immunoblotting 48 h after the last transfection. ERα validated Stealth RNAi and Stealth RNAi negative controls from Invitrogen were used. Duplexes (0.9 nM final) were introduced in cells using Lipofectamine RNAiMAX reagent (Invitrogen) by reverse transfection according to the manufacturer's protocol. Similar results were obtained with the two different ERα duplexes. The BCL2 P1 promoter constructs with wild-type or mutant CRE sites were as previously described 17 .
Immunoblot analysis, antibodies and immmunofluorescence microscopy. WCEs were prepared in RIPA buffer (10 mM Tris at pH 7.5, 150 mM NaCl, 10 mM EDTA, 1% NP40, 0.1% SDS, 1% sodium sarcosyl, 0.2 mM PMSF, 10 μg ml -1 leupeptin, 1 mM dithiothreitol). Nuclear extracts were prepared as previously described 29 .
Immunoblotting was performed as we have previously described 29 .
Antibodies against NF-κB family members p65 (sc-372) and RelB (sc-226); or AP-1 members JunB (sc-46), JunD (sc-74), c-Fos (sc-7202), Fra-1 (sc-183), Fra-2 (sc-604) and Bcl-2 (sc-492); or against Snail (Snai1, sc-10432) or Lamin B (sc-6217), were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies against c-Jun and ERα were purchased from Cell Signaling (Danvers, MA) and NeoMarker (Fremont, CA), respectively. The E-cadherin, fibronectin, and γ-catenin antibodies were purchased from BD Transduction Lab (Franklin Lakes, NJ), and the β-actin (AC-15) and cyclin D1 (Ab-3) antibodies were from Sigma and Oncogene (Boston, MA), respectively. Immunofluorescence microscopy was performed as we have published previously 25 .
EMSA. Nuclear extracts were prepared and samples (5 μg) subjected to binding and EMSA as previously described 2 . The sequences of the oligonucleotide containing the consensus AP-1 element and NF-κB element upstream of the c-Myc promoter are as follows: AP-1, 5ʹ-GATCCGCTTGATGACTCAGCCGGAAG-3ʹ; NF-κB, 5ʹ-GATCCAAGTCCGGGTTTTCCCCAACC-3ʹ. ) were suspended at 4 °C in Matrigel (0.2 ml, 6.3 mg ml -1 ; BD Biosciences, Bedford, MA), an extracellular matrix extracted from Engelbreth-Holm-Swarm mouse tumours, and added to a preset Matrigel layer in 24-well plates as previously described 25 . The top Matrigel cell layers were covered with culture medium containing 10% FBS.
Migration and invasion assays. Suspensions of 1-2.5 × 10 5 MCF-7 or Hs578T cells were layered, in triplicate, in the upper compartments of a Transwell (Costar, Cambridge, MA) on an 8-mm diameter polycarbonate filter (8 μm pore size), and incubated at 37 °C for the indicated times. All migration assays were performed two to three times, in triplicate. For invasion assays, filters were precoated with 60 μg Matrigel. Migration of the cells to the lower side of the filter was evaluated with the acid phosphatase enzymatic assay using p-nitrophenyl phosphate and A 410 determination. The mean ± s.d. are presented. All invasion assays were performed two times, in triplicate.
Gene expression and statistical analysis. The Van de Vijver Breast carcinoma microarray dataset (reporter number NM_006509) 6 was accessed using the ONCOMINE Cancer Profiling Database (www.oncomine.org). The dataset includes 69 ERα-negative and 226 ERα-positive human primary breast carcinoma samples. Box plots, depicting the distribution of RELB expression within each ERα group and a Student's t-test giving a P value for the comparison of RELB expression between the two ERα groups were obtained directly through the Oncomine 3.0 software. The line within the box represents the median expression value for each group, and the upper and lower edges of the box indicate the 75 th and 25 th percentile of the distribution, respectively. The lines (whiskers) emerging from each box extend to the smallest and largest observations; the black dots outside the ends of the whiskers are outlier data points. 
